About the Program
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, participants should be better able to:
- Describe HIV epidemiologic and demographic trends that form the basis for HIV prevention and testing guidelines
- Apply major guidelines to the identification of individuals at risk for HIV infection and to determine the appropriateness of using PrEP in individual patients
- Describe research findings that support current HIV treatment guidelines
- Provide effective antiretroviral therapy to a variety of different patient types based on HIV treatment guidelines
Release Date: May 24, 2023
Expiration Date: May 24, 2024
Media: Internet
Estimated time to complete each Module: 30 minutes
Faculty
Michelle Cespedes, MD
Associate Professor of Medicine, Division of Infectious Diseases
The Mount Sinai Hospital
New York, New York
|
Helena Kwakwa, MD
Director of HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania |
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts |
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois |
Joint Accreditation Statement
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Credit Designation
Physician Continuing Medical Education and Continuing Pharmacy Education
Case 1 (HIV Prevention Options):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-220-H01-P
Type of Activity: Knowledge
Case 2 (PrEP Initiation):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-221-H01-P
Type of Activity: Knowledge
Case 3 (Potential Switch to Long-Acting ART):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRAPRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-222-H01-P
Type of Activity: Knowledge
Case 4 (Stable Switch):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-223-H01-P
Type of Activity: Knowledge
Case 5 (HIV and Pregnancy):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-224-H01-P
Type of Activity: Knowledge
Case 6 (Aging with HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-225-H01-P
Type of Activity: Knowledge
Case 7 (Barriers to PrEP):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-320-H99-P
Type of Activity: Knowledge
Case 8 (HIV Resistance and Drug Interactions):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-321-H99-P
Type of Activity: Knowledge
Case 9 (Barriers to Oral ART):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-322-H99-P
Type of Activity: Knowledge
Case 10 (Stable Switch in 53-Year-Old Man):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Postgraduate Institute for Medicine designates this continuing
medical education activity for .50 contact hour(s)(0.05 CEUs) of the
Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-323-H99-P
Type of Activity: Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners and
others in
control of educational content to disclose all thier financial
relationships with ineligible companies. All identified conflicts of
interest (COI) are thoroughly vetted and mitigated
according to PIM policy. PIM is committed to providing its learners with
high quality accredited continuing education activities and related
materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of an ineleigible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the content of this
CME activity:
Michelle Cespedes, MD
- Consultant/Advisory Board: ViiV, Gilead
Helena Kwakwa, MD
- Grant/Research Support: ViiV (relationship ended)
Paul Sax, MD
- Grant/Research Support: Gilead, GSK/ViiV
- Consultant/Advisory Board: Gilead, GSK/ViiV, Merck, Janssen
- Other (Editorial Boards): Clinical Infectious Diseases, UpToDate, NEJM Journal Watch
Renslow Sherer, MD
- Grant/Research Support: Gilead
The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose
Method of Participation and Request for Credit
1) Go to http://www.cmeuniversity.com/
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 17944 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) (If applicable) Complete the Post-test
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files
9) For Pharmacists: Upon successfully completing the post-test with a
score of 75% or better and the activity evaluation form, transcript
information will be sent to the NABP CPE Monitor Service.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Computer System Requirements
This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
|